Primary outcome: prevention of ulcer · ulceration caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ulcer healing · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Primary outcome: adverse events (skin sensitisation at 2 months) · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Secondary outcome: quality of life · ulceration caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: acceptability of treatment · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Costs · ulceration caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Physician Global Assessment (clinical signs, complete response) · People with erosive oral lichen planus
Fluocinonide in adhesive base showed no clear difference in physician Global Assessment (clinical signs, complete response) compared with placebo; GRADE not reported.
1 finding from 1 review
Partial response (>33% improvement) · People with erosive oral lichen planus
Fluocinonide in adhesive base showed no clear difference in partial response (>33% improvement) compared with placebo; GRADE not reported.
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Pain reduction (VAS 0-10) · People with erosive oral lichen planus
Clobetasol propionate ointment 0.05% showed no clear difference in pain reduction (VAS 0-10) compared with 5% topical mesalazine gel in adhesive base; GRADE not reported.
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review